Skip to content
ppharmaranks
Menu
Class IIOngoing

Cinacalcet Hydrochloride Tablets recall

FDA recall D-0450-2026 · initiated Mar 16, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Apr 22, 2026How we research

Cipla USA, Inc. recalled Cinacalcet Hydrochloride Tablets in Mar 2026 — an FDA Class II recall (D-0450-2026) because CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot, expiry: 4PB0215, 4PB0216, exp March-2026; 4PB0515, 4PB0516, exp September-2026; 4PB0517, exp September-2026; 5PB0167, exp January-2027

Quantity recalled: 96,096 bottles

Details

Product
Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-411-02
Recalling company
Cipla Limited
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Mar 16, 2026
FDA report date
Apr 22, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Cinacalcet Hydrochloride Tablets recalled?
Cipla USA, Inc. recalled Cinacalcet Hydrochloride Tablets in Mar 2026 — an FDA Class II recall (D-0450-2026) because CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Cinacalcet Hydrochloride Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0450-2026 was: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Is a recalled Cinacalcet Hydrochloride Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Cinacalcet Hydrochloride Tablets are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot, expiry: 4PB0215, 4PB0216, exp March-2026; 4PB0515, 4PB0516, exp September-2026; 4PB0517, exp September-2026; 5PB0167, exp January-2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0450-2026.

Source: openFDA Drug Enforcement record D-0450-2026

← All drug recalls